General Court to hear drug competition cases following fines
The EU’s General Court will this month hear three competition cases involving generic companies, with the first—brought by Slovenian business Krka—being heard today.
The two other hearings, concerning Teva and Mylan Laboratories, will take place on Thursday, June 22 and Tuesday, June 27 respectively.
In 2014, the European Commission imposed fines which totalled €427.7 million ($477 million) on French pharmaceutical company Servier, as well five generic companies.
Besides the three companies mentioned, the two other drugs manufacturers also fined were Niche/Unichem and Matrix, which is now part of Mylan.
The companies were accused of taking part in several deals all aimed at protecting Servier’s perindopril drug, a blood pressure treatment, from EU competition.
According to a press release, Servier and the five generic companies have brought separate actions for the annulment of the Commission’s fines before the General Court.
Alternatively, the companies have asked the court to reduce the fines.
Today’s news:
Biopharma must target unpopularity, says Allergan
Intellia granted China patent for CRISPR technology
Fed Circuit invalidates diagnostics patents
J&J reveals obesity and 3D printing collaborations
Merck granted its first CRISPR patent in Australia
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
